Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Request Sample
Cell and Gene Therapy Market, by Therapy Type (Cell Therapy and Gene Therapy), by Indication (Cardiovascular Disease, Cancer, Genetic Disorders, Infectious Diseases, Neurological Disorders, and Others), by Scale of Operation (In-house and Outsourced), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), was valued at US$ 6,020.0 million in 2017 and is projected to exhibit a CAGR of 21.9% during the forecast period (2018 – 2026), as highlighted in a new report published by Coherent Market Insights.
Launch of novel cell and gene therapy by market players is expected to augment the market growth
Key players in the market are focused on launching novel cell and gene therapies in order to treat various diseases and address the critical unmet needs of patients. For instance, in June 2011, Fibrocell Technologies, Inc. received approval from the U.S. Food and Drug Administration (FDA) for Azficel-T, which can be used for the treatment of nasolabial fold wrinkles.
*The Download PDF brochure only consist of Table of Content, Research Framework, and Research Methodology.
Request PDF Research Report Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/2475
Moreover, in November 2011, New York Blood Center, Inc. received approval from the FDA for Hemacord. It is indicated for unrelated donor hematopoietic progenitor cell transplantation procedures and in patients with disorders affecting the hematopoietic system that are inherited, acquired, or results from myeloablative treatment in children. In October 2017, Kite Pharma received approval from the U.S. FDA for Yescarta (axicabtagene ciloleucel) which is used for the treatment of adults with large B-cell lymphoma. It was the first chimeric antigen receptor (CAR) T-cell therapy to receive FDA approval for large B-cell lymphoma.
Key players in the market are focused on adopting strategies such as mergers and acquisitions to enhance their product portfolio. For instance, in June 2017, Johnson & Johnson acquired Actelion Ltd. Moreover, in October 2017, Gilead Sciences acquired Kite Pharma. Kite Pharma is involved in developing chimeric antigen receptor T-cell therapy, to recognize and attack malignant cells.
Browse 35 Market Data Tables and 28 Figures spread through 164 Pages and in-depth TOC on Cell and Gene Therapy Market, by Therapy Type (Cell Therapy and Gene Therapy), By Indication (Cardiovascular Disease, Cancer, Genetic Disorders, Infectious Diseases, Neurological Disorders, and Others), By Scale of Operation (In-house and Outsourced), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Global Forecast to 2026.
To know the latest trends and insights prevalent in the cell and gene therapy market Press Release, click the link below: https://www.coherentmarketinsights.com/press-release/cell-and-gene-therapy-market-to-surpass-us-354-billion-by-2026-1275
Key Takeaways of the Cell and Gene Therapy Market:
- The global cell and gene therapy market is expected to exhibit a CAGR of 21.9% during the forecast period owing to the increasing prevalence of cardiovascular diseases, cancer, and neurological disorders.
- Among therapy type, the gene therapy segment held a dominant position in the cell and gene therapy market in 2018. For instance, in November 2018, Pharma Intelligence Company estimated that around 55% of the pipeline is of gene therapy, and medicines that are delivered in vivo.
- Among indication, the cancer segment held a dominant position in the cell and gene therapy market in 2018, as majority of cell and gene therapies consist of cancer medicines in development stage.
- Key players operating in the global cell and gene therapy market are Amgen, Biogen, BioMarin Pharmaceuticals, Bristol-Myers Squibb Company, GlaxoSmithKline, Novartis, Pfizer, Regeneron Pharmaceuticals and Sanofi, Spark Therapeutics, Agilis Biotherapeutics, Angionetics AVROBIO, Freeline Therapeutics, Horama, MeiraGTx, Myonexus Therapeutics, Nightstar Therapeutics, Kolon TissueGene, Inc., JCR Pharmaceuticals Co., Ltd., and MEDIPOST.
Access research reports that are tailored specifically for you and your organization in order to explore practical growth strategies and recommendations
Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/2475
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
